Solving the Diagnostic Puzzle: Biopsies and Bloodwork

Diagnosing Monoclonal Immunoglobulin Deposition Disease (MIDD) is often described as solving a puzzle with three essential pieces: a kidney biopsy, blood and urine testing, and a bone marrow biopsy ^[1]. Because MIDD is a “monoclonal gammopathy of renal significance” (MGRS), the kidney damage is caused by a group of cells that may not show up on standard tests ^[2].

The First Piece: The Kidney Biopsy

The kidney biopsy is the most important tool for identifying MIDD. It involves taking a tiny sample of kidney tissue and examining it in three different ways:

1. Light Microscopy: The pathologist may look for nodular glomerulosclerosis, which are round, scarred-looking “nodules” within the kidney’s filters (glomeruli). However, this finding is suggestive but not highly specific, and may be absent ^[3][4].
2. Immunofluorescence (IF): This test uses glowing dyes to see where proteins are stuck. In MIDD, the dye will often show a “linear” (straight line) pattern along the membranes of the kidney ^[5][6]. Crucially, the biopsy is typically Congo red negative ^[7][8]. A negative stain supports a non-amyloid process, but does not absolutely exclude amyloid because of sampling or technical limitations, and amyloid and MIDD can occasionally coexist.
3. Electron Microscopy (EM): This is the critical step. Using a microscope that can see ultrastructural deposits, pathologists look for powdery or granular deposits that are “non-organized” ^[9]. This distinguishes MIDD from other diseases where proteins form long fibers or tubes ^[10]. In some cases, the EM is the only way to find the disease if the IF test is weak or negative ^[9].
4. Mass Spectrometry: If the diagnosis is still unclear, proteomic typing such as mass spectrometry may be used to identify the specific proteins.

The Second Piece: Blood and Urine Tests

Once the kidney biopsy suggests MIDD, doctors must look for the abnormal proteins in your circulation. These tests include:

• Serum Free Light Chain (sFLC) Assay: This measures the amount of kappa (κ) and lambda (λ) light chains in your blood ^[5]. Doctors look at the ratio between the two and the dFLC (the difference between the “involved” or abnormal chain and the healthy one) to track how well treatment is working ^[11].
• Immunofixation (IFE): This test (performed on both blood and urine) is a highly sensitive way to find a “monoclonal” protein—a signature of the abnormal cell clone ^[2]. Note that for HCDD, sFLC tests may be uninformative, and clinicians must monitor the relevant heavy-chain markers.
• Important Note: Up to 75% of patients with certain types of MGRS lesions may have normal blood or urine tests on initial screening ^[12]. A “normal” blood test does not mean you don’t have MIDD if the kidney biopsy shows the characteristic deposits, as detection rates differ substantially by subtype ^[11].

The Third Piece: The Bone Marrow Biopsy

Even if your blood tests are normal, your doctor will likely recommend a bone marrow biopsy. This is because the underlying clone making the proteins lives in the marrow.

• Finding the Clone: Doctors use flow cytometry to find even a very small group of abnormal plasma cells or B-cells ^[13].
• FISH Testing: This checks the genetics of those cells for specific abnormalities (like a “translocation” called t(11;14)) ^[2][14]. While it helps characterize the clone and may inform options, it is not a universal stand-alone predictor of the most effective regimen.

Completeness Checklist

Your diagnostic reports should ideally contain these specific details: